Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Adalimumab (Humira) is recommended as an option for use within NHS Wales for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. |
|||
|
|||
Medicine details |
|||
| Medicine name | adalimumab (Humira®) | ||
| Formulation | 40 mg solution for injection | ||
| Reference number | 3118 | ||
| Indication | Treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies |
||
| Company | AbbVie Ltd | ||
| BNF chapter | Gastro-intestinal system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 3916 | ||
| NMG meeting date | 02/11/2016 | ||
| AWMSG meeting date | 07/12/2016 | ||
| Date of issue | 04/01/2017 | ||
| Date of last review | August 2020 | ||